Our observations were consistent with previous studies demonstrating that serum levels of anti-Ro52 antibodies are linked to activity and/or severity of multiple disease manifestations in anti-Jo-1 antibody-positive individuals that include myositis, xerophthalmia/xerostomia, and ILD (37). The gene discussed is TRIM21; the disease is interstitial lung disease.